Stockscreener 앱 받기
24.28
2.25%
-0.5631
전일 마감가:
$24.84
열려 있는:
$24.78
하루 거래량:
380.86K
Relative Volume:
0.33
시가총액:
$2.88B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
20.57
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
+2.75%
1개월 성능:
+5.24%
6개월 성능:
+10.56%
1년 성능:
+64.95%
1일 변동 폭
$24.22
$24.83
1주일 범위
$23.41
$25.01
52주 변동 폭
$14.47
$26.16
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.23 | 2.88B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.00 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.32 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.46 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.20 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.47 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
BlackRock, Inc. Reduces Stake in Catalyst Pharmaceuticals Inc - GuruFocus
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the BofA Securities H - GuruFocus
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 - The Manila Times
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist? - Yahoo Finance
Catalyst Pharmaceuticals Leadership Team to Share Rare Disease Strategy at Major BofA Healthcare Conference - Stock Titan
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock performs better than its underlying earnings growth over last five years - simplywall.st
Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy Now - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals to Release First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - Nasdaq
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewswire
Earnings Watch: When Catalyst Pharmaceuticals Will Reveal Q1 2025 ResultsKey Date for Rare Disease Leader - Stock Titan
BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33 - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from Bof - GuruFocus
Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from BofA to $34 | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - MSN
11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts - Insider Monkey
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip - Yahoo Finance
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - BioSpace
Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment - marketscreener.com
Catalyst Pharmaceuticals Announces Health Canada’s - GlobeNewswire
First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status - Stock Titan
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy – Company AnnouncementFT.com - Financial Times
Lambert Eaton Myasthenic Syndrome Market 2025: Growth, - openPR.com
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday - Yahoo Finance
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? - MSN
Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cornercap Investment Counsel Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - MSN
Strong Revenue, Drug Performance Lift Catalyst Shares - FXEmpire
With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - simplywall.st
CPRX stock soars to all-time high of $24.8 amid robust growth - Investing.com
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Catalyst Pharmaceuticals Inc 주식 (CPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Option Exercise |
2.24 |
44,904 |
100,585 |
113,777 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 06 '25 |
Sale |
21.67 |
180,096 |
3,902,680 |
68,873 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Sale |
22.09 |
44,904 |
991,929 |
68,873 |
0.37%
0.04%
자본화:
|
볼륨(24시간):